No­var­tis, Am­gen rack up their first PhI­II suc­cess in a crowd­ed CGRP mi­graine drug field

No­var­tis and its part­ners at Am­gen say that their CGRP mi­graine drug erenum­ab (AMG 334) came through in a Phase III study, beat­ing a place­bo re­sponse in cut­ting the av­er­age num­ber of episodes pa­tients ex­pe­ri­enced each month. And an­a­lysts can now start run­ning the num­bers again as they slice and dice the da­ta to see if any of the sev­er­al ri­vals in this field can do bet­ter.

The two phar­ma gi­ants en­rolled 577 mi­graine suf­fer­ers for the piv­otal tri­al, track­ing a base­line of 8 mi­graine days per month. The pa­tients in the drug arm get­ting a sub­cu­ta­neous 70 mg dose one month­ly saw that drop an av­er­age of 2.9 days, which was sig­nif­i­cant­ly bet­ter than the 1.8-day drop from a place­bo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.